A study utilizing a bispecific variable heavy domain antibody to target both EphA2 and EphA3, members of the Eph receptor family, which are found in developing but not adult tissues and are enriched in glioblastoma and especially GBM stem cells (GCS), showed decreased tumorigenesis and increased differentiation in a recurrent BM model. This evidence concerns the gene EPHA3 and glioblastoma.